|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
61,413,000 |
Market
Cap: |
9.10(B) |
Last
Volume: |
702,454 |
Avg
Vol: |
504,275 |
52
Week Range: |
$114.17 - $208.42 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Repligen is a life sciences company that develops and commercializes bioprocessing technologies and systems used in the process of manufacturing biological drugs. Co.'s bioprocessing business is comprised of:Filtration, which includes XCell Alternating Tangential Flow systems that are used in upstream perfusion cell culture processing; Chromatography, which includes products used in downstream purification, development, manufacturing and quality control of biological drugs; Process Analytics, which complements and supports its Filtration, Chromatography and Proteins franchises; and Proteins, which are represented by its Protein A affinity ligands and cell culture growth factor products.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
1,500 |
Total Buy Value |
$0 |
$0 |
$0 |
$238,260 |
Total People Bought |
0 |
0 |
0 |
1 |
Total Buy Transactions |
0 |
0 |
0 |
3 |
Total Shares Sold |
40,296 |
45,669 |
50,307 |
151,828 |
Total Sell Value |
$7,357,263 |
$8,416,817 |
$9,119,818 |
$30,980,273 |
Total People Sold |
2 |
4 |
5 |
6 |
Total Sell Transactions |
3 |
5 |
7 |
17 |
End Date |
2024-02-29 |
2023-11-28 |
2023-05-30 |
2022-05-30 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Hunt Anthony |
Chief Executive Officer |
|
2024-05-21 |
4 |
AS |
$166.36 |
$3,377,283 |
D/D |
(20,072) |
163,177 |
|
- |
|
Pax Margaret |
|
|
2024-05-16 |
4 |
A |
$0.00 |
$0 |
D/D |
701 |
793 |
|
- |
|
Madaus Martin D |
|
|
2024-05-16 |
4 |
A |
$0.00 |
$0 |
D/D |
701 |
2,998 |
|
- |
|
Muir Glenn P |
|
|
2024-05-16 |
4 |
A |
$0.00 |
$0 |
D/D |
701 |
8,283 |
|
- |
|
Barthelemy Nicholas |
|
|
2024-05-16 |
4 |
A |
$0.00 |
$0 |
D/D |
701 |
3,468 |
|
- |
|
Mhatre Rohin |
|
|
2024-05-16 |
4 |
A |
$0.00 |
$0 |
D/D |
701 |
3,046 |
|
- |
|
Konstantinov Konstantin |
|
|
2024-05-16 |
4 |
A |
$0.00 |
$0 |
D/D |
701 |
1,921 |
|
- |
|
Dawes Karen A |
|
|
2024-05-16 |
4 |
A |
$0.00 |
$0 |
D/D |
803 |
88,170 |
|
- |
|
Eglinton Manner Carrie |
|
|
2024-05-16 |
4 |
A |
$0.00 |
$0 |
D/D |
701 |
3,493 |
|
- |
|
Gebski Christine |
See Remarks |
|
2024-05-14 |
4 |
D |
$163.34 |
$54,556 |
D/D |
(334) |
27,419 |
|
- |
|
Kuriyel Ralf |
Senior VP, R&D |
|
2024-05-14 |
4 |
D |
$163.34 |
$87,224 |
D/D |
(534) |
23,726 |
|
- |
|
Bylund James |
Chief Operating Officer |
|
2024-04-02 |
4 |
D |
$182.95 |
$81,230 |
D/D |
(444) |
20,591 |
|
- |
|
Hunt Anthony |
Chief Executive Officer |
|
2024-03-18 |
4 |
GD |
$0.00 |
$0 |
D/D |
2,000 |
183,249 |
|
- |
|
Pax Margaret |
|
|
2024-03-18 |
4 |
A |
$0.00 |
$0 |
D/D |
92 |
92 |
|
- |
|
Kuriyel Ralf |
Senior VP, R&D |
|
2024-03-11 |
4 |
S |
$193.73 |
$681,348 |
D/D |
(3,517) |
24,260 |
|
21% |
|
Kuriyel Ralf |
Senior VP, R&D |
|
2024-03-11 |
4 |
OE |
$86.10 |
$109,433 |
D/D |
1,271 |
27,777 |
|
- |
|
Hunt Anthony |
Chief Executive Officer |
|
2024-03-08 |
4 |
AS |
$195.49 |
$3,298,632 |
D/D |
(16,707) |
185,249 |
|
-19% |
|
Hunt Anthony |
Chief Executive Officer |
|
2024-03-08 |
4 |
OE |
$16.55 |
$17 |
D/D |
1 |
201,956 |
|
- |
|
Hunt Anthony |
Chief Executive Officer |
|
2024-03-07 |
4 |
D |
$195.72 |
$561,129 |
D/D |
(2,867) |
201,955 |
|
- |
|
Bylund James |
Chief Operating Officer |
|
2024-03-07 |
4 |
D |
$195.72 |
$236,038 |
D/D |
(1,206) |
21,035 |
|
- |
|
Kuriyel Ralf |
Senior VP, R&D |
|
2024-03-07 |
4 |
D |
$195.72 |
$75,548 |
D/D |
(386) |
26,506 |
|
- |
|
Gebski Christine |
See Remarks |
|
2024-03-07 |
4 |
D |
$195.72 |
$75,548 |
D/D |
(386) |
27,753 |
|
- |
|
Bylund James |
Chief Operating Officer |
|
2024-03-05 |
4 |
D |
$195.52 |
$4,301 |
D/D |
(22) |
22,241 |
|
- |
|
Hunt Anthony |
Chief Executive Officer |
|
2024-03-05 |
4 |
D |
$195.52 |
$1,422,408 |
D/D |
(7,275) |
204,822 |
|
- |
|
Kuriyel Ralf |
Senior VP, R&D |
|
2024-03-04 |
4 |
D |
$193.99 |
$26,189 |
D/D |
(135) |
26,892 |
|
- |
|
647 Records found
|
|
Page 1 of 26 |
|
|